Predicting and preventing heart failure in type 2 diabetes
The burden of heart failure among people with type 2 diabetes is increasing globally. People
with comorbid type 2 diabetes and heart failure often have worse outcomes than those with …
with comorbid type 2 diabetes and heart failure often have worse outcomes than those with …
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
AJ Scheen - Expert Review of Clinical Pharmacology, 2023 - Taylor & Francis
Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health …
Importance Novel therapies for type 2 diabetes can reduce the risk of cardiovascular
disease and chronic kidney disease progression. The equitability of these agents' …
disease and chronic kidney disease progression. The equitability of these agents' …
Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients …
Importance Type 2 diabetes (T2D) and heart failure (HF) prevalence are rising in the US.
Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose …
Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose …
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
SB Nicholas, KB Daratha, RZ Alicic… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim Guideline‐directed medical therapy (GDMT) is designed to improve clinical outcomes.
The study aim was to assess GDMT prescribing rates and prescribing‐persistence …
The study aim was to assess GDMT prescribing rates and prescribing‐persistence …
Prescription patterns of cardiovascular-and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease
JA Lamprea-Montealegre, E Madden… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE To assess the prevalence and correlates of prescription of sodium–glucose
cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1 …
cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1 …
Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD
LP Gregg, DJ Ramsey, JM Akeroyd, SA Jafry… - American Journal of …, 2023 - Elsevier
Rationale & Objective Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among medicare-insured adults following a new diagnosis of …
SJ Cromer, JC Lauffenburger, R Levin… - Diabetes Care, 2023 - Am Diabetes Assoc
OBJECTIVE To examine the association of race/ethnicity and socioeconomic deprivation
with initiation of guideline-recommended diabetes medications with cardiovascular benefit …
with initiation of guideline-recommended diabetes medications with cardiovascular benefit …
Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the Department of …
Background Multiple clinical trials have demonstrated significant cardiovascular benefit with
use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes …
use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes …
Pharmacologic treatment of type 2 diabetes in the US, Sweden, and Israel
OBJECTIVE To characterize and compare glucose-lowering medication use in type 2
diabetes in the US, Sweden, and Israel, including adoption of newer medications and …
diabetes in the US, Sweden, and Israel, including adoption of newer medications and …